- Home
- IMPP vs NTHI Comparison
IMPP vs NTHI Comparison
Compare IMPP & NTHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMPP
- NTHI
- Stock Information
- Founded
- IMPP 1981
- NTHI 2008
- Country
- IMPP Greece
- NTHI United States
- Employees
- IMPP N/A
- NTHI N/A
- Industry
- IMPP Marine Transportation
- NTHI Biotechnology: Pharmaceutical Preparations
- Sector
- IMPP Consumer Discretionary
- NTHI Health Care
- Exchange
- IMPP Nasdaq
- NTHI Nasdaq
- Market Cap
- IMPP 103.9M
- NTHI 110.9M
- IPO Year
- IMPP N/A
- NTHI N/A
- Fundamental
- Price
- IMPP $3.14
- NTHI $5.10
- Analyst Decision
- IMPP
- NTHI
- Analyst Count
- IMPP 0
- NTHI 0
- Target Price
- IMPP N/A
- NTHI N/A
- AVG Volume (30 Days)
- IMPP 131.7K
- NTHI 284.4K
- Earning Date
- IMPP 08-26-2025
- NTHI 01-01-0001
- Dividend Yield
- IMPP N/A
- NTHI N/A
- EPS Growth
- IMPP N/A
- NTHI N/A
- EPS
- IMPP 1.21
- NTHI N/A
- Revenue
- IMPP $138,368,325.00
- NTHI $79,990.00
- Revenue This Year
- IMPP $8.79
- NTHI N/A
- Revenue Next Year
- IMPP $40.11
- NTHI N/A
- P/E Ratio
- IMPP $2.59
- NTHI N/A
- Revenue Growth
- IMPP N/A
- NTHI 13.52
- 52 Week Low
- IMPP $2.12
- NTHI $3.20
- 52 Week High
- IMPP $4.55
- NTHI $25.00
- Technical
- Relative Strength Index (RSI)
- IMPP 50.23
- NTHI N/A
- Support Level
- IMPP $2.99
- NTHI N/A
- Resistance Level
- IMPP $3.29
- NTHI N/A
- Average True Range (ATR)
- IMPP 0.12
- NTHI 0.00
- MACD
- IMPP -0.01
- NTHI 0.00
- Stochastic Oscillator
- IMPP 47.06
- NTHI 0.00
About IMPP Imperial Petroleum Inc.
Imperial Petroleum Inc is a provider of international seaborne transportation services to oil producers, refineries, and commodities traders. It owns and operates a fleet of six medium-range product tankers that carry refined petroleum products such as gasoline, diesel, fuel oil, and jet fuel, as well as edible oils and chemicals.
About NTHI NeOnc Technologies Holdings Inc. Common Stock
NeOnc Technologies Holdings Inc. is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company product includes NEO100, which commenced Phase 2a clinical trials, which is used for treating glioblastoma, and has Orphan Drug and Fast Track designation from the United States Food and Drug Administration ("FDA").